Social media campaign spreads the word with #NoTime4Migraines

Promius Pharma launched a social media campaign to raise awareness for people with the severe headache disorder. 

By Suzanne Elvidge • Aug. 31, 2016

Weighing in on EpiPen, PhRMA calls for reforms at FDA

In a blog post, PhRMA President Stephen Ubl called on the FDA to improve the review process for combination products such as Mylan's EpiPen. 

By Ned Pagliarulo • Aug. 31, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Express Scripts puts pricing cap on diabetes drugs

The latest move is one of a series of initiatives the PBM has launched to lower patient costs and push back against ever-rising drug prices. 

By Lisa LaMotta • Aug. 31, 2016

Mylan bites back at system with generic EpiPen

Responding to continued criticism of its steep price increases for EpiPen, Mylan will launch a generic copy of its own drug — at half the cost.

By Lisa LaMotta • Aug. 29, 2016

Mylan caves on price after Clinton call-out

Backlash to Epipen price hikes continue, pushing the company to make concessions on price for some patients. 

By Lisa LaMotta • Aug. 25, 2016

Specialty pharma working to bring EpiPen competitor to market

Adamis Pharmaceuticals' epinephrine pre-filled syringe could be competition for the price-hiking Mylan, but regulatory setbacks have delayed market entry. 

By Suzanne Elvidge • Aug. 25, 2016

#HowEyeSeeIt campaign to bring retinal disease into clear view

A patient advocacy group campaign highlights the growing need for vision loss treatments and the interest from pharmaceutical companies. 

By Suzanne Elvidge • Aug. 24, 2016

Study: 'Opt-out' option key to support of mandatory HPV vaccination

The results underscore the resistance to mandatory vaccinations, despite the links between HPV and several cancers. 

By Suzanne Elvidge • Aug. 24, 2016

Diabetes prevalence varies widely across US, study shows

A new analysis from the American Diabetes Association gives county-by-county detail to the growth in diabetes prevalence.

By Suzanne Elvidge • Aug. 24, 2016

How Mylan ended up with an EpiPen monopoly

A strong marketing program and some old-fashioned good luck made EpiPen Mylan's first $1 billion product. 

By Lisa LaMotta • Aug. 24, 2016

With PDUFA date for rucaparib set, Clovis eyes rebound

A high-profile failure of Clovis' lung cancer drug earlier this year had led the company to cut a third of its staff and pin its hopes on rucaparib. 

By Ned Pagliarulo • Aug. 24, 2016

Mylan feels heat from Congress after 400% EpiPen price hike

The drugmaker is the latest to have its pricing practices called into question by Congress. 

By Lisa LaMotta • Aug. 22, 2016

FDA expedites Aspen's prostate drug ahead of merger

The newly merged company will provide women's health, men's health and OTC products. 

By Nicole Gray • Aug. 18, 2016

GSK enters pay-for-performance deal for gene therapy

If Strimvelis does not work in treated children, GlaxoSmithKline must refund the Italian government. 

By Nicole Gray • Aug. 17, 2016

Ipsen hopes to be David to Allergan's Goliath

The French biotech is hoping a new indication for its boulinum toxin Dysport will allow it to compete more effectively with Allergan's market-leading Botox. 

By Nicole Gray • Aug. 17, 2016

ALS Ice Bucket Challenge funds new study

Cytokinetics is fully enrolled in a Phase 3 study that the ALS Foundation helped bankroll. 

By Lisa LaMotta • Aug. 17, 2016

JAMA: PCSK9s should cost $4536, but don't

Roughly nine million Americans with hypercholesterolemia are eligible for PCSK9 inhibitors based on labeling, but JAMA estimates the drugs could cost the health system $120 billion. 

By Nicole Gray • Aug. 17, 2016

Boehringer seeks real-world data to support reversal agent

The pharmaceutical company is hoping to bolster sales of Pradaxa with real-wrold data supporting the use of its anti-coagulant reversal agent Praxabind. 

By Nicole Gray • Aug. 16, 2016

Drug pricing studies anger industry, ICER pushes back

The Institute for Clinical and Economic Review has singled out a number of drugs for being overpriced in recent cost-effectiveness reports. 

By Ned Pagliarulo • Aug. 12, 2016

MannKind maps out Afrezza strategy

After Sanofi broke off its partnership, Mannkind has scaled up to meet the demands of marketing Afrezza by itself. But a turnaround is going to take more than just resources. 

By Lisa LaMotta • Aug. 10, 2016

Why certain drugs don't make the formulary

Express Scripts and CVS Health revealed their new formulary exclusion lists, but why certain drugs don't make the cut isn't always obvious. 

By Lisa LaMotta • Aug. 10, 2016

BIO president defends Orphan Drug Act after op-ed criticism

Jim Greenwood, president and CEO of BIO, contends that the Orphan Drug Act has been a success, despite recent attacks saying it facilitates high drug pricing. 

By Nicole Gray • Aug. 9, 2016

Does MannKind have a shot at a successful Afrezza re-launch?

Matthew Pfeffer, Mannkind's chief financial officer, is trying convince investors that it will. 

By Nicole Gray • Aug. 9, 2016

Allergan's Vraylar launch a success, despite trial failure

Allergan is making headway with its branded pharma business after divesting its generics and distribution businesses.  

By Lisa LaMotta • Aug. 8, 2016

Novo Nordisk sees pricing challenges 'intensifying'

The Danish drugmaker hopes Tresiba can fuel growth moving forward, particularly as pharmacy benefit managers such as Express Scripts tighten the screws on diabetes drug pricing. 

By Ned Pagliarulo • Aug. 8, 2016